---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-042903"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T18:19:20.865413+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Alaunos Therapeutics VP Finance resigns; Ferdinand Groenewald appointed as replacement via consulting agreement

## Summary
- Michael Wong resigned as VP Finance effective Feb 23, 2024.
- Ferdinand Groenewald appointed as VP Finance effective Feb 22, 2024 via consulting agreement.
- Consulting agreement pays $15,000 per month; indefinite term with 30-day termination notice.
- Groenewald previously served as CFO and CAO of Muscle Maker, Inc.; is a CPA.
- Agreement includes customary indemnification and business expense reimbursement.

## SEC filing metadata
- accession: 0001193125-24-042903
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119312524042903/0001193125-24-042903-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119312524042903/d929353d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-042903
- JSON: https://secwatch.observer/filing/0001193125-24-042903.json
- Plain text: https://secwatch.observer/filing/0001193125-24-042903.txt

## Key facts
- Executive change
  Michael Wong resigned as Vice President, Finance at Alaunos Therapeutics, Inc..
  - Action: resigned
  - Role: Vice President, Finance
  source text: On February 15, 2024, Michael Wong gave notice of his resignation as Vice President, Finance, of Alaunos Therapeutics, Inc. (the "Company"), effective February 23, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312524042903/0001193125-24-042903-index.htm
- Executive change
  Ferdinand Groenewald was appointed as Vice President, Finance at Alaunos Therapeutics, Inc..
  - Action: appointed
  - Role: Vice President, Finance
  source text: On February 22, 2024, the Company and Ferdinand Groenewald entered into a consulting agreement (the “Consulting Agreement”), effective February 22, 2024, pursuant to which Mr. Groenewald will lead accounting and financial reporting activities of the Company. Mr. Groenewald will serve as the Company’s Vice President, Finance.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312524042903/0001193125-24-042903-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.